Chee M Ng

faculty photo
Research Assistant Professor of Pediatrics
Director, NVIDIA CUDA Research Center
Member, The Institute for the Translational Medicine and Therapeutics (ITMAT)
Research Investigator, Cancer Therapeutic Program, Abramson Cancer Center, University of Pennsylvania
Department: Pediatrics

Contact information
Clinical Pharmacology and Therapeutics
Children Hospital of Philadelphia
Room 4010 CTRB Building
3501 Civic Center Blvd
Philaldelphia, PA 19104
Office: 267-4262826
Education:
B.S. (Pharmacy)
State University of New York at Buffalo, 1991.
PharmD (High Honor)
University of Illinois at Chicago, 1995.
PhD (Pharmaceutical Science)
University of North Carolina at Chapel Hill, 2002.
Permanent link
 

Description of Itmat Expertise

Model-based drug discovery and development of therapeutic monoclonal antibodies; Phase I/II study and PK/PD study of anti-cancer agents. System pharmacology modeling of anti-cancer drugs in preclinical model and clinical patients. Modeling and simulation of clinical pharmacology/translational medicine data.

Description of Research Expertise

Complex system pharmacology-based approach to guide the preclinical/clinical development of the therapeutic monoclonal antibodies in cancer. Pharmacogenomic study of FcRn ontogeny and its effects on therapeutic monoclonal antibodies in adult and pediatric population. Structure-activity relationships of the FcRn/FcR mutation and pharmacology of the therapeutic monoclonal antibody in preclinical models and clinical patients. Novel GPU-based MCPEM algorithm for complex population pharmacokinetic and pharmacodynamic data analysis. Fast GPU-based modeling to study the pharmacodynamic effects of anti-vascular therapies using DCE-MRI imaging data in cancer patients. Phase I/II study and PK/PD of anti-cancer agents. System pharmacology modeling of anti-cancer drugs in preclinical model and clinical patients. Exposure-response modeling for selecting optimal dose of buprenorphine in patients with Neonatal Abstinence Syndrome.

Selected Publications

Ng CM: Novel Hybrid GPU-CPU Implementation of Parallelized Monte Carlo Parametric Expectation Maximization Estimation Method for Population Pharmacokinetic Data Analysis AAPS J 15(4): 1212-1221, 2013.

Choo EF, Ng CM, Berry L, Belvin M, Koh NL, Merchant M, Salphati L: Pharmacokinetic-pharmacodynamic modeling of combination efficacy effect from administration of a MEK inhibitor, GDC-0972 and PI3K inhibitor, GDC-0941 in A2058 xenografts. Cancer Chemother Pharmacol 71(1): 133-43, 2013.

Shellhaas R, Ng CM, Barks JD, Bhatt-Metha V. : Population pharmacokinetics of Phenobarbital in infants with neonatal encephalopathy treated with therapeutic hypothermia. Ped Crit Care Med 14(2): 194-202, 2013.

Hsu YH, Ferl GZ, Ng CM: GPU-accelerated Nonparametric Kinetic Analysis of DCE-MRI Data from Glioblastoma Patients Treated with Bevacizumab. Magn Reson Imaging 31(4): 618-23, 2013.

Han T, Everett RS, Proctor WR, Ng CM, Costales CL, Brouwer KLR, Thakker DR. : Organic Cation Transporter 1 (OCT1/mOct1) Is Localized in the Apical Membrane of Caco-2 Cell Monolayers and Enterocytes. Mol Pharmacol 84(2): 182-9, 2013.

Zuo X, Ng CM, Barrett JS, Luo A, Zhang B, Deng C, Xi L, Cheng K, Ming Y, Yang G, Pei Q, Zhu L, Yuan H, Liao H, Ding J, Wu D, Zhou Y, Jing N, Huang Z.: Effects of CUP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients:a population pharmacokinetic analysis. Pharmacogenet Genomics 23(5): 251-61, 2013.

Ng CM, Patnaik A, Beeram M, Lin CC, Bauer RJ, Takimoto CH: Mechanism-based pharmacokinetic/pharmacodynamic model for troxacitabine-induced neutropenia in cancer patients. Cancer Chemother Pharmacol 67(5): 985-94, 2011.

Ng CM, Bai S, Takimoto CH, Tolcher AW: Mechanism-based receptor-binding model to describe the population pharmacokinetic and pharmacodynamic of an anti-α5β1 integrin monoclonal antibody (voloxicimab) in cancer patients. Cancer Chemother Pharmacol 65(2): 207-17, 2010.

Takimoto CH, Graham M, Lockwood G, Ng CM, Goetz A, Zafar H, Greenslade D, Remick SC, Sharma S, Mani S, Ramanathan R, Doroshow J, Hamilton A, Mulkerin D, Ivy P, Egorin M, Dahut W, Grem JL: Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function. Clin Cancer Res 13(16): 4832-9, 2007.

Putnam W, Li J, Haggstrom J, Ng CM, Fischer SK, Cheu M, Deniz Y, Lowman H, Fielder P, Visich J, Joshi A, Jumbe S: Use of quantitative pharmacology in the development of HAE1, a high-affinity anti-IgE monoclonal antibody. AAPS Journal 10(1): 425-30, 2008.

Takimoto CH, Ng CM: Pharmacokinetics and Pharmacodynamics. Cancer: Principles and Practices of Oncology. De Vita V, Lawrence T, Rosenberg S (eds.). Lippincott Williams & Wilkins, Philadelphia, PA, 2008.

back to top
Last updated: 10/10/2013
The Trustees of the University of Pennsylvania